The gene therapy company uniQure NV has set the price of an underwritten public offering of 4.9 million shares on Nasdaq at $46 per share giving gross proceeds of $225 million. Goldman Sachs & Co LLC and SVB Leerink are joint book-runners for the offering, which attracted more than the targeted amount of $200 million.
